These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 28269754)

  • 1. Evaluation of PIK3CA mutations as a biomarker in Chinese breast carcinomas from Western China.
    Cheng J; Fu S; Wei C; Tania M; Khan MA; Imani S; Zhou B; Chen H; Xiao X; Wu J; Fu J
    Cancer Biomark; 2017; 19(1):85-92. PubMed ID: 28269754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients.
    Ahmad F; Badwe A; Verma G; Bhatia S; Das BR
    Med Oncol; 2016 Jul; 33(7):74. PubMed ID: 27282497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between the Prevalence of Somatic Mutations in PIK3CA Gene in Tumors and Clinical and Morphological Characteristics of Breast Cancer Patients.
    Filipenko ML; Os'kina NA; Oskorbin IA; Mishukova OV; Ovchinnikova LK; Gershtein ES; Kushlinskii NE
    Bull Exp Biol Med; 2017 Jun; 163(2):250-254. PubMed ID: 28726194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Three Real-Time PCR Assays for the Detection of PIK3CA Somatic Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Breast Carcinomas.
    Lambert A; Salleron J; Lion M; Rouyer M; Lozano N; Leroux A; Merlin JL; Harlé A
    Pathol Oncol Res; 2019 Jul; 25(3):1117-1123. PubMed ID: 30426328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.
    Dirican E; Kaya Z; Gullu G; Peker I; Ozmen T; Gulluoglu BM; Kaya H; Ozer A; Akkiprik M
    Asian Pac J Cancer Prev; 2014; 15(21):9327-33. PubMed ID: 25422220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deciphering the impact of somatic mutations in exon 20 and exon 9 of PIK3CA gene in breast tumors among Indian women through molecular dynamics approach.
    Sudhakar N; Priya Doss CG; Thirumal Kumar D; Chakraborty C; Anand K; Suresh M
    J Biomol Struct Dyn; 2016; 34(1):29-41. PubMed ID: 25679319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
    Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
    PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.
    Dunlap J; Le C; Shukla A; Patterson J; Presnell A; Heinrich MC; Corless CL; Troxell ML
    Breast Cancer Res Treat; 2010 Apr; 120(2):409-18. PubMed ID: 19418217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PIK3CA somatic alterations in invasive breast cancers: different spectrum from Caucasians to Chinese detected by next generation sequencing.
    Jia M; Liao N; Chen B; Zhang G; Wang Y; Li X; Cao L; Mok H; Ren C; Li K; Li C; Wen L; Lin J; Wei G; Balch CM
    Breast Cancer; 2021 May; 28(3):644-652. PubMed ID: 33386585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIK3CA gene mutations in breast carcinoma in Malaysian patients.
    Ching-Shian Leong V; Jabal MF; Leong PP; Abdullah MA; Gul YA; Seow HF
    Cancer Genet Cytogenet; 2008 Dec; 187(2):74-9. PubMed ID: 19027487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [PIK3CA gene mutations in Chinese women with HR
    Wu SF; Wang XF; Liu YY; Xia C; Liang ZY; Zeng X
    Zhonghua Bing Li Xue Za Zhi; 2022 Dec; 51(12):1246-1250. PubMed ID: 36480834
    [No Abstract]   [Full Text] [Related]  

  • 12. Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria.
    Harlé A; Lion M; Lozano N; Husson M; Harter V; Genin P; Merlin JL
    Oncol Rep; 2013 Mar; 29(3):1043-52. PubMed ID: 23314198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer.
    Gasch C; Oldopp T; Mauermann O; Gorges TM; Andreas A; Coith C; Müller V; Fehm T; Janni W; Pantel K; Riethdorf S
    Mol Oncol; 2016 Oct; 10(8):1330-43. PubMed ID: 27491860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
    Chia SKL; Martin M; Holmes FA; Ejlertsen B; Delaloge S; Moy B; Iwata H; von Minckwitz G; Mansi J; Barrios CH; Gnant M; Tomašević Z; Denduluri N; Šeparović R; Kim SB; Jakobsen EH; Harvey V; Robert N; Smith J; Harker G; Zhang B; Eli LD; Ye Y; Lalani AS; Buyse M; Chan A
    Breast Cancer Res; 2019 Mar; 21(1):39. PubMed ID: 30867034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system.
    Shimoi T; Hamada A; Yamagishi M; Hirai M; Yoshida M; Nishikawa T; Sudo K; Shimomura A; Noguchi E; Yunokawa M; Yonemori K; Shimizu C; Kinoshita T; Fukuda T; Fujiwara Y; Tamura K
    Cancer Sci; 2018 Aug; 109(8):2558-2566. PubMed ID: 29906308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials.
    Jank P; Karn T; van Mackelenbergh M; Lindner J; Treue D; Huober J; Engels K; Solbach C; Diebold K; Marmé F; Müller V; Schneeweiss A; Sinn HP; Fehm T; Schem C; Stickeler E; Fasching P; Budczies J; Felder B; Nekljudova V; Holtschmidt J; Untch M; Denkert C; Loibl S
    Clin Cancer Res; 2024 Sep; 30(17):3868-3880. PubMed ID: 38837894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphatidylinositol 3-kinase (PI3KCA) oncogene mutation analysis and gene expression profiling in primary breast cancer patients.
    Kandula M; Chennaboina KK; Ys AR; Raju S
    Asian Pac J Cancer Prev; 2013; 14(9):5067-72. PubMed ID: 24175777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIK3CA mutation is a favorable prognostic factor in esophageal cancer: molecular profile by next-generation sequencing using surgically resected formalin-fixed, paraffin-embedded tissue.
    Yokota T; Serizawa M; Hosokawa A; Kusafuka K; Mori K; Sugiyama T; Tsubosa Y; Koh Y
    BMC Cancer; 2018 Aug; 18(1):826. PubMed ID: 30115035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PIK3CA mutations in in situ and invasive breast carcinomas.
    Miron A; Varadi M; Carrasco D; Li H; Luongo L; Kim HJ; Park SY; Cho EY; Lewis G; Kehoe S; Iglehart JD; Dillon D; Allred DC; Macconaill L; Gelman R; Polyak K
    Cancer Res; 2010 Jul; 70(14):5674-8. PubMed ID: 20551053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of PIK3CA, BRAF, and KRAS mutations in breast carcinomas among Chinese women in Qinghai.
    Wang YL; Dai X; Li YD; Cheng RX; Deng B; Geng XX; Zhang HJ
    Genet Mol Res; 2015 Nov; 14(4):14840-6. PubMed ID: 26600545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.